• Je něco špatně v tomto záznamu ?

Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson's Disease and Other Synucleinopathies

M. Skorvanek, E. Feketeova, MM. Kurtis, J. Rusz, K. Sonka,

. 2018 ; 9 (-) : 376. [pub] 20180525

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18023977

Grantová podpora
NV16-28914A MZ0 CEP - Centrální evidence projektů

Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by repeated episodes of REM sleep-related vocalizations and/or complex motor behaviors. Definite diagnosis of RBD is based on history and polysomnography, both of which are less accessible due to the lack of trained specialists and high cost. While RBD may be associated with disorders like narcolepsy, focal brain lesions, and encephalitis, idiopathic RBD (iRBD) may convert to Parkinson's disease (PD) and other synucleinopathies in more than 80% of patients and it is to date the most specific clinical prodromal marker of PD. Identification of individuals at high risk for development of PD is becoming one of the most important topics for current PD-related research as well as for future treatment trials targeting prodromal PD. Furthermore, concomitant clinical symptoms, such as subtle motor impairment, hyposmia, autonomic dysfunction, or cognitive difficulties, in subjects with iRBD may herald its phenoconversion to clinically manifest parkinsonism. The assessment of these motor and non-motor symptoms in iRBD may increase the sensitivity and specificity in identifying prodromal PD subjects. This review evaluates the diagnostic accuracy of individual rating scales and validated single items for screening of RBD and the role and accuracy of available clinical, electrophysiological, imaging, and tissue biomarkers in predicting the phenoconversion from iRBD to clinically manifest synucleinopathies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18023977
003      
CZ-PrNML
005      
20180713104518.0
007      
ta
008      
180709s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fneur.2018.00376 $2 doi
035    __
$a (PubMed)29887829
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Skorvanek, Matej $u Department of Neurology, Faculty of Medicine, P. J. Safarik University, Kosice, Slovakia. Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia.
245    10
$a Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson's Disease and Other Synucleinopathies / $c M. Skorvanek, E. Feketeova, MM. Kurtis, J. Rusz, K. Sonka,
520    9_
$a Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by repeated episodes of REM sleep-related vocalizations and/or complex motor behaviors. Definite diagnosis of RBD is based on history and polysomnography, both of which are less accessible due to the lack of trained specialists and high cost. While RBD may be associated with disorders like narcolepsy, focal brain lesions, and encephalitis, idiopathic RBD (iRBD) may convert to Parkinson's disease (PD) and other synucleinopathies in more than 80% of patients and it is to date the most specific clinical prodromal marker of PD. Identification of individuals at high risk for development of PD is becoming one of the most important topics for current PD-related research as well as for future treatment trials targeting prodromal PD. Furthermore, concomitant clinical symptoms, such as subtle motor impairment, hyposmia, autonomic dysfunction, or cognitive difficulties, in subjects with iRBD may herald its phenoconversion to clinically manifest parkinsonism. The assessment of these motor and non-motor symptoms in iRBD may increase the sensitivity and specificity in identifying prodromal PD subjects. This review evaluates the diagnostic accuracy of individual rating scales and validated single items for screening of RBD and the role and accuracy of available clinical, electrophysiological, imaging, and tissue biomarkers in predicting the phenoconversion from iRBD to clinically manifest synucleinopathies.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Feketeova, Eva $u Department of Neurology, Faculty of Medicine, P. J. Safarik University, Kosice, Slovakia. Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia.
700    1_
$a Kurtis, Monica M $u Movement Disorders Unit, Department of Neurology, Hospital Ruber Internacional, Madrid, Spain.
700    1_
$a Rusz, Jan $u Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia. Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czechia.
700    1_
$a Sonka, Karel $u Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia.
773    0_
$w MED00174552 $t Frontiers in neurology $x 1664-2295 $g Roč. 9, č. - (2018), s. 376
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29887829 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180713104812 $b ABA008
999    __
$a ind $b bmc $g 1315964 $s 1020895
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c - $d 376 $e 20180525 $i 1664-2295 $m Frontiers in neurology $n Front. neurol. $x MED00174552
GRA    __
$a NV16-28914A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace